There are more than 100 different types of arthritis, but osteoarthritis (OA) is the most common—impacting 32.5 Million US adults and creating an overall economic burden of...
Pre-existing condition. This is a term we heard thrown around a lot at the start of 2020. It’s still a part of our day-to-day vocabulary, especially if you're one of the...
When pharma brands become fully digitally enabled, market access pathways are optimized and providers have the tools they need to begin patients on your therapy rapidly and...
The 2022 State of Mental Health in America report highlights that 24.7% of adults with a mental illness in 2019 reported an unmet need for treatment—this number has seen a...
As pharmaceutical companies evolve toward digital-first commercial models, U.S. market access strategies seem to be lagging in the digital revolution. Companies face many...
Non-adherence to prescribed therapy can create extraordinary risks for patients. Even when provided with correct diagnoses and effective treatment plans, patients can often...
There may be no greater threat to patient outcomes than the current barriers to therapy access—especially for specialty medications.
Every day, patients switch to new therapies because of disease progression, side effects, affordability or other factors—potentially delaying patient recoveries, negatively...
It’s a problem with an enormous impact on patients that has been nearly impossible to solve: Brand-eligible patients are out there, but they’ve been misdiagnosed or, even...
If you’re a life science marketer, chances are you’ve been hearing about the difference artificial...
At the recent Re:Imagine Pharma Marketing virtual conference, I was excited to present on how...
In our series on the challenges MS patients face in starting and staying on therapy, we’ve explored three key areas...
